FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010680101> ?p ?o ?g. }

• W3010680101 endingPage "e000347" @default.
• W3010680101 startingPage "e000347" @default.
• W3010680101 abstract "Background Patients with advanced rare cancers have poor prognosis and few treatment options. As immunotherapy is effective across multiple cancer types, we aimed to assess pembrolizumab (programmed cell death 1 (PD-1) inhibitor) in patients with advanced rare cancers. Methods In this open-label, phase 2 trial, patients with advanced rare cancers whose tumors had progressed on standard therapies, if available, within the previous 6 months were enrolled in nine tumor-specific cohorts and a 10th cohort for other rare histologies. Pembrolizumab 200 mg was administered intravenously every 21 days. The primary endpoint was non-progression rate (NPR) at 27 weeks; secondary endpoints were safety and tolerability, objective response rate (ORR), and clinical benefit rate (CBR). Results A total of 127 patients treated between August 15, 2016 and July 27, 2018 were included in this analysis. At the time of data cut-off, the NPR at 27 weeks was 28% (95% CI, 19% to 37%). A confirmed objective response (OR) was seen in 15 of 110 (14%) evaluable patients (complete response in one and partial response in 14). CBR, defined as the percentage of patients with an OR or stable disease ≥4 months, was 38% (n=42). Treatment was ongoing in 11 of 15 patients with OR at last follow-up. In the cohort with squamous cell carcinoma (SCC) of the skin, the NPR at 27 weeks was 36%, ORR 31%, and CBR 38%. In patients with adrenocortical carcinoma (ACC), NPR at 27 weeks was 31%, ORR 15%, and CBR 54%. In the patients with carcinoma of unknown primary (CUP), NPR at 27 weeks was 33%, ORR 23%, and CBR 54%. In the paraganglioma–pheochromocytoma cohort, NPR at 27 weeks was 43%, ORR 0%, and CBR 75%. Treatment-related adverse events (TRAEs) occurred in 66 of 127 (52%) patients, and 12 (9%) had grade ≥3 TRAEs. The most common TRAEs were fatigue (n=25) and rash (n=17). There were six deaths, all of which were unrelated to the study drug. Conclusions The favorable toxicity profile and antitumor activity seen in patients with SCC of skin, ACC, CUP, and paraganglioma–pheochromocytoma supports further evaluation of pembrolizumab in this patient population. Trial registration number NCT02721732" @default.
• W3010680101 created "2020-03-23" @default.
• W3010680101 creator A5001804696 @default.
• W3010680101 creator A5005194857 @default.
• W3010680101 creator A5005436649 @default.
• W3010680101 creator A5007020035 @default.
• W3010680101 creator A5008786567 @default.
• W3010680101 creator A5009388082 @default.
• W3010680101 creator A5016068761 @default.
• W3010680101 creator A5022557533 @default.
• W3010680101 creator A5026095888 @default.
• W3010680101 creator A5032970786 @default.
• W3010680101 creator A5035230107 @default.
• W3010680101 creator A5037920180 @default.
• W3010680101 creator A5039846489 @default.
• W3010680101 creator A5042245860 @default.
• W3010680101 creator A5043675371 @default.
• W3010680101 creator A5044840107 @default.
• W3010680101 creator A5044942439 @default.
• W3010680101 creator A5045197829 @default.
• W3010680101 creator A5046416890 @default.
• W3010680101 creator A5051182441 @default.
• W3010680101 creator A5051328429 @default.
• W3010680101 creator A5051823619 @default.
• W3010680101 creator A5054595254 @default.
• W3010680101 creator A5058115259 @default.
• W3010680101 creator A5059433894 @default.
• W3010680101 creator A5061237827 @default.
• W3010680101 creator A5062097723 @default.
• W3010680101 creator A5068368047 @default.
• W3010680101 creator A5070385327 @default.
• W3010680101 creator A5071750897 @default.
• W3010680101 creator A5071800834 @default.
• W3010680101 creator A5073135717 @default.
• W3010680101 creator A5076426660 @default.
• W3010680101 creator A5079762645 @default.
• W3010680101 creator A5082358197 @default.
• W3010680101 creator A5084349853 @default.
• W3010680101 creator A5087117639 @default.
• W3010680101 creator A5088853428 @default.
• W3010680101 creator A5089393952 @default.
• W3010680101 creator A5091121810 @default.
• W3010680101 date "2020-03-01" @default.
• W3010680101 modified "2023-10-18" @default.
• W3010680101 title "Phase 2 study of pembrolizumab in patients with advanced rare cancers" @default.
• W3010680101 cites W1967352082 @default.
• W3010680101 cites W1995452486 @default.
• W3010680101 cites W1996343979 @default.
• W3010680101 cites W2019607817 @default.
• W3010680101 cites W2024902613 @default.
• W3010680101 cites W2029409133 @default.
• W3010680101 cites W2045660847 @default.
• W3010680101 cites W2060070314 @default.
• W3010680101 cites W2071988003 @default.
• W3010680101 cites W2076668534 @default.
• W3010680101 cites W2100158834 @default.
• W3010680101 cites W2109485845 @default.
• W3010680101 cites W2137264248 @default.
• W3010680101 cites W2138134458 @default.
• W3010680101 cites W2143772132 @default.
• W3010680101 cites W2143902340 @default.
• W3010680101 cites W2171081063 @default.
• W3010680101 cites W2236559807 @default.
• W3010680101 cites W2258624258 @default.
• W3010680101 cites W2266111816 @default.
• W3010680101 cites W2267333092 @default.
• W3010680101 cites W2516326590 @default.
• W3010680101 cites W2527905628 @default.
• W3010680101 cites W2594309985 @default.
• W3010680101 cites W2601943254 @default.
• W3010680101 cites W2622499649 @default.
• W3010680101 cites W2637886930 @default.
• W3010680101 cites W2742469146 @default.
• W3010680101 cites W2753127471 @default.
• W3010680101 cites W2789288884 @default.
• W3010680101 cites W2801426251 @default.
• W3010680101 cites W2804858690 @default.
• W3010680101 cites W2805968856 @default.
• W3010680101 cites W2891449271 @default.
• W3010680101 cites W2891965082 @default.
• W3010680101 cites W2895476867 @default.
• W3010680101 cites W2897002925 @default.
• W3010680101 cites W4292166992 @default.
• W3010680101 doi "https://doi.org/10.1136/jitc-2019-000347" @default.
• W3010680101 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7078933" @default.
• W3010680101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32188704" @default.
• W3010680101 hasPublicationYear "2020" @default.
• W3010680101 type Work @default.
• W3010680101 sameAs 3010680101 @default.
• W3010680101 citedByCount "79" @default.
• W3010680101 countsByYear W30106801012020 @default.
• W3010680101 countsByYear W30106801012021 @default.
• W3010680101 countsByYear W30106801012022 @default.
• W3010680101 countsByYear W30106801012023 @default.
• W3010680101 crossrefType "journal-article" @default.
• W3010680101 hasAuthorship W3010680101A5001804696 @default.
• W3010680101 hasAuthorship W3010680101A5005194857 @default.
• W3010680101 hasAuthorship W3010680101A5005436649 @default.

• next